Experimental bias may explain risk for high-grade prostate cancers in the PCPT

Shafer, Emily
July 2008
Hem/Onc Today;7/25/2008, Vol. 9 Issue 13, p30
The article discusses a study on the risk for high-grade prostate cancers among patients enrolled in the Prostate Cancer Prevention Trial who received finasteride. Study researchers conducted three analyzes to examine the validity of the claim that high-grade prostate cancer is related to increased biopsy sensitivity with finasteride in 15,990 men. They concluded that biases on the effect of finasteride on cancer diagnosis may explain the increased number of prostate cancer in patients who received such drug.


Related Articles

  • Fewer Men Being Screened for Prostate Cancer. Norton, Amy // Tennessee Tribune;11/26/2015, Vol. 26 Issue 48, p8B 

    The article reports on the decline in incidence and the decline in the proportion of men who are diagnosed with prostate cancer in the U.S.

  • `Multiply-by-2' rule preserves PSA usefulness for finasteride patients.  // Modern Medicine;Dec98, Vol. 66 Issue 12, p39 

    Presents an abstract of the study `Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial,' by G. L. Andriole, H. A. Guess, J. I. Epstein, et al., which appeared in...

  • Prospective evaluation of prostate cancer stage at diagnosis in Poland - multicenter study. Dobruch, Jakub; Borówka, Andrzej; Modzelewska, Elza; Tyloch, Janusz; Misterek, Bartosz; Czapkowicz, Ewa; Bres-Niewada, Ewa // Central European Journal of Urology;Sep2009, Vol. 62 Issue 3, p150 

    Introduction. Prostate cancer (PCa) is one of the most common cancers diagnosed in men. Its presentation has evolved substantially since the introduction of prostatespecific antigen (PSA) measurement in blood. The incidence of organ confined PCa has increased. Locally advanced cases are...

  • Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Thörmer, Gregor; Otto, Josephin; Reiss-Zimmermann, Martin; Seiwerts, Matthias; Moche, Michael; Garnov, Nikita; Franz, Toni; Do, Minh; Stolzenburg, Jens-Uwe; Horn, Lars-Christian; Kahn, Thomas; Busse, Harald // European Radiology;Aug2012, Vol. 22 Issue 8, p1820 

    Objectives: To evaluate the influence of the choice of b values on the diagnostic value of the apparent diffusion coefficient (ADC) for detection and grading of prostate cancer (PCa). Methods: Forty-one patients with biopsy-proven PCa underwent endorectal 3-T MRI before prostatectomy. Different...

  • Transrectal versus transperineal 14-core prostate biopsy in detection of prostate cancer: A comparative evaluation at the same Institution. Cerruto, Maria Angela; Vianello, Fabio; D'Elia, Carolina; Artibani, Walter; Novella, Giovanni // Archivio Italiano di Urologia, Andrologia: Organo Ufficiale di S;2014, Vol. 86 Issue 4, p284 

    Background: The ideal bioptic strategy for CaP detection is still to be completely defined. The aim of our study is to compare transperineal (TP) and transrectal (TR) approaches, in a 14-core initial prostate biopsy for CaP detection. Material and methods: A prospective controlled study was...

  • The Effectiveness of transperineal template guided mapping biopsy compared to transrectal ultrasound guided biopsy in detecting prostate cancer. Dunne, R. S.; Bouchier-Hayes, D. M. // BMC Proceedings;1/14/2015, p1 

    A conference paper about impact of transperineal template guided mapping biopsy (TTMB) in comparisons to transrectal ultrasound guided biopsy (TRUS) in detecting prostate cancer and mentions that TTMB can be used as a step in the management pathway of patients with suspected prostate cancer.

  • MDxHealth Reports Positive Results for its Prostate Cancer Diagnostic Test.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p837 

    The article reports that leading molecular diagnostics company MDxHealth SA in Liege, Belgium has announced positive results for its Prostate ConfirmMDx(tm), a diagnostic test for prostate cancer. The test can help urologists identify patients who have a true negative biopsy from those who may...

  • A Clinicopathological Profile of Prostate Cancer in Trinidad and Tobago. Hosein, Ian; Sukhraj, Rajendra; Goetz, Lester; Rambarran, Nastassia; Persaud, Satyendra // Advances in Urology;7/17/2016, p1 

    Aim. To conduct a clinicopathological review of all prostate biopsies performed in a tertiary referral centre in Trinidad and Tobago over a period of 30 months. Methods. The records of all patients who had prostate biopsies from January 2012 to July 2014 were reviewed. Clinical and pathologic...

  • The effect of urologist experience on choosing active surveillance for prostate cancer. Chu, William; Kim, Brian; Slezak, Jeff; Harrison, Teresa; Gelfond, Joy; Jacobsen, Steven; Chien, Gary // World Journal of Urology;Nov2015, Vol. 33 Issue 11, p1701 

    Purpose: To evaluate the impact of the urologist's experience in selecting active surveillance (AS) versus immediate treatment (IT) for low-risk prostate cancer. Methods: Men with low-risk prostate cancer were enrolled from March 2011 to August 2013 at 13 medical centers in Kaiser Permanente...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics